<DOC>
	<DOCNO>NCT02155582</DOCNO>
	<brief_summary>This study aim analyze study drug body relationship drug level safety patient advance cancer treat copanlisib different dose group .</brief_summary>
	<brief_title>Copanlisib Pharmacodynamic Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Histologically confirm diagnosis follow NHL : follicular lymphoma grade , lymphoplasmacytic lymphoma / Waldenström macroglobulinemia , transform indolent lymphoma , diffuse large Bcell lymphoma , Burkitt lymphoma , mantle cell lymphoma , peripheral Tcell lymphoma , relapse refractory , 1 prior chemoimmunotherapy immunotherapybased regimen ( ) OR Advanced / refractory solid tumor high prevalence ( ≥30 % ) PIK3CA PTEN alteration : Breast uterine cancer ( endometrium cancer also nonendometrial uterine cancer ) , lung ( squamous cell ) , cervical , head neck , prostate , ovarian cancer Biopsyaccessible tumor Male female patient equal 18 year age NHL patient must least 1 bidimensionally measurable lesion accord modify Cheson criterion . Patients solid tumor must least 1 solid tumor lesion measurable compute tomography magnetic resonance image accord Response Evaluation Criteria Solid Tumors Version 1.1 ( RECIST 1.1 ) criterion Eastern Cooperative Oncology Group performance status 2 &lt; Life expectancy least 3 month Adequate bone marrow , liver , renal function assess laboratory requirement conduct within 7 day first dose study drug Left ventricular ejection fraction &gt; equal low limit normal institution Previous concurrent cancer distinct primary site histology NHL solid tumor , patient enrol study , within 5 year treatment start EXCEPT curatively treat cervical cancer situ , nonmelanoma skin cancer , situ breast cancer , situ prostate carcinoma Gleason score &lt; equal 6 prostatespecific antigen &lt; 10 ng/mL , superficial bladder tumor [ Ta ( noninvasive tumor ) , Tis ( carcinoma situ ) T1 ( tumor invades lamina propria ) ] Known lymphomatous involvement brain leptomeningeal involvement ; solid tumor patient central nervous system ( CNS ) metastases treatment complete &lt; 3 month enrollment lesion unstable progress magnetic resonance imaging scan perform within 1 month enrollment unstable symptom CNS metastases Any illness medical condition unstable could jeopardize safety patient / compliance study Current diagnosis type 1 type 2 diabetes mellitus HbA1c &lt; equal 8.5 % fast blood glucose &lt; equal 160 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>